Disclaimer: This article is intended solely for informational and educational purposes only. It does not constitute medical advice.
Sevoflurane and isoflurane are the most widely used volatile anesthetic agents in modern general anesthesia. Although they are both halogenated ethers, their specific properties give rise to meaningful differences in clinical performance. Understanding these differences remains relevant to anesthesiologists selecting an agent for a given patient and procedure.
The most fundamental distinction between the two agents lies in solubility. Sevoflurane has a blood/gas partition coefficient of approximately 0.68 to 0.69, compared with roughly 1.4 for isoflurane, meaning sevoflurane is considerably less soluble in blood (Behne et al., 1999; Patel & Goa, 1996). This lower solubility translates directly into faster pharmacokinetics: alveolar concentrations of sevoflurane equilibrate with inspired concentrations more quickly, so induction of anesthesia is more rapid, and because wash-out from the body also occurs faster, recovery tends to be quicker as well (Behne et al., 1999).
In terms of potency, sevoflurane’s minimum alveolar concentration (MAC) is roughly 1.7–2.05% in adults, compared with about 1.15% for isoflurane, indicating that isoflurane is the more potent agent on a per-volume basis even though sevoflurane acts faster (Patel & Goa, 1996; Behne et al., 1999).
A further practical difference concerns airway tolerability. Sevoflurane has a pleasant, non-pungent odor and produces minimal airway irritation, which allows it to be used for smooth inhalational mask induction in both children and adults. Isoflurane, by contrast, has a pungent smell and is more likely to provoke breath-holding, coughing, or laryngospasm, making it far less suitable for induction by mask (Patel & Goa, 1996). For this reason, sevoflurane has become the preferred agent for inhalational induction, particularly in pediatric anesthesia.
Clinical comparisons of recovery generally favor sevoflurane. An early review found that emergence, extubation, and orientation occurred several minutes earlier with sevoflurane than with isoflurane in both ambulatory and inpatient surgical settings, a finding attributable to sevoflurane’s lower tissue solubility (Patel & Goa, 1996). More recent clinical reviews have reinforced this pattern while noting that these time differences, though statistically significant, are often modest and do not always translate into earlier hospital discharge (Brioni et al., 2017).
Cardiovascular effects are broadly similar between the two agents, as both produce dose-dependent decreases in blood pressure and systemic vascular resistance with preserved cardiac output at clinically relevant concentrations. However, isoflurane is more prone to inducing tachycardia, particularly with rapid increases in inspired concentration, whereas sevoflurane tends to produce a more stable heart rate profile (Patel & Goa, 1996; Brioni et al., 2017).
Both agents have demonstrated cardioprotective and, in some experimental models, neuroprotective properties in adult tissue subjected to ischemic injury, largely through overlapping pathways involving reduced apoptosis and inflammatory cytokine expression, although these effects appear to reverse toward neurotoxicity in neonatal and aged brain tissue in animal studies (Neag et al., 2020).
Metabolically, sevoflurane undergoes greater hepatic biotransformation than isoflurane, releasing inorganic fluoride and the metabolite hexafluoroisopropanol, along with a degradation product (Compound A) formed on contact with carbon dioxide absorbents; despite theoretical nephrotoxicity concerns raised by animal studies, clinical experience has not established a corresponding risk in humans (Behne et al., 1999; Patel & Goa, 1996). Isoflurane, undergoing minimal metabolism, carries a correspondingly lower theoretical burden of metabolite-related toxicity.
Overall, sevoflurane offers practical advantages in induction comfort and speed of emergence, making it especially useful for mask induction and ambulatory surgery, while isoflurane remains a well-established, cost-effective option for maintenance anesthesia with a long track record of safety. The choice between the two often comes down to the clinical context, patient population, institutional cost, and logistical considerations.
References
Behne, M., Wilke, H. J., & Harder, S. (1999). Clinical pharmacokinetics of sevoflurane. Clinical Pharmacokinetics, 36(1), 13–26. https://doi.org/10.2165/00003088-199936010-00002
Brioni, J. D., Varughese, S., Ahmed, R., & Bein, B. (2017). A clinical review of inhalation anesthesia with sevoflurane: from early research to emerging topics. Journal of Anesthesia, 31(5), 764–778. https://doi.org/10.1007/s00540-017-2375-6
Neag, M.-A., Mitre, A.-O., Catinean, A., & Mitre, C.-I. (2020). An overview on the mechanisms of neuroprotection and neurotoxicity of isoflurane and sevoflurane in experimental studies. Brain Research Bulletin. https://doi.org/10.1016/j.brainresbull.2020.10.011
Patel, S. S., & Goa, K. L. (1996). Sevoflurane: A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia. Drugs, 51(4), 658–700. https://doi.org/10.2165/00003495-199651040-00009